期刊
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
卷 43, 期 11, 页码 3255-3275出版社
WILEY
DOI: 10.1002/hed.26809
关键词
angiotensin converting enzyme inhibitor; angiotensin II receptor blocker; head and neck cancer; renin-angiotensin-aldosterone system; SEER-Medicare
资金
- NIDCR [R01 DE028529-01, R01 DE028282-01]
- Population Health Shared Resource, University of Colorado Cancer Center Support Grant [P30CA44688]
The study found that the usage of ARB is associated with improved overall survival and cancer-specific survival among head and neck cancer patients with chronic kidney disease or hypertension.
Background Preclinical evidence suggests a link between the renin-angiotensin system and oncogenesis. We aimed to explore the impact of angiotensin-converting enzyme inhibitors (ACEi) and angiotensin II receptor blockers (ARB) in head and neck cancer (HNC). Methods Over 5000 patients were identified from the Surveillance, Epidemiology, and End Results-Medicare linked dataset and categorized according to ACEi and ARB and diagnoses of chronic kidney disease (CKD) or hypertension (HTN). Overall survival (OS) and cancer-specific survival (CSS) were compared using Cox multivariable regression (MVA), expressed as hazard ratios (HR) with 95% confidence intervals (95%CI). Results No significant MVA associations for OS or CSS were found for ACEi. Compared to patients with CKD/HTN taking ARB, those with CKD/HTN not taking ARB experienced worse OS (HR 1.28, 95%CI 1.09-1.51, p = 0.003) and CSS (HR 1.23, 95%CI 1.00-1.50, p = 0.050). Conclusions ARB usage is associated with improved OS and CSS among HNC patients with CKD or HTN.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据